Lipid + Metabolic

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/201

encourage image

There's no tags or description

Looks like no tags are added yet.

202 Terms

1
New cards

Which lipoprotein is the predominant atherogenic particle?

LDL

2
New cards

Which lipoprotein carries most cholesterol in fasting serum?

LDL

3
New cards

Which lipoprotein returns loose cholesterol to the liver for excretion?

HDL

4
New cards

Which lipoprotein transports dietary triglycerides to muscle and fat cells?

Chylomicrons

5
New cards

Which lipoprotein carries liver-produced triglycerides to tissues?

VLDL

6
New cards

Which transitional lipoprotein forms after VLDL delivers triglycerides?

IDL

7
New cards

What does LDL-C measure?

Mass of cholesterol inside LDL particles

<p>Mass of cholesterol inside LDL particles</p>
8
New cards

What does LDL-P measure?

Number of LDL particles

9
New cards

When may LDL-P testing be useful?

High triglycerides or discordant LDL-C results

10
New cards

What is the lecture’s optimal total cholesterol level?

<200 mg/dL?

11
New cards

What is the lecture’s optimal triglyceride level?

<150 mg/d

12
New cards

What HDL level is listed as optimal in the lipid goal table?

≥60 mg/dL

13
New cards

What HDL goal is stated for men?

40 mg/dL


14
New cards

What HDL goal is stated for women?

50 mg/dL


15
New cards

What LDL goal applies to borderline or intermediate ASCVD risk?

<100 mg/d

16
New cards

What LDL goal applies to high ASCVD risk?

<70 mg/d

17
New cards

What LDL goal applies to very high ASCVD risk?

<55 mg/dL


18
New cards

What non-HDL goal accompanies an LDL goal <100 mg/dL?

<130 mg/dL


19
New cards

What non-HDL goal accompanies an LDL goal <70 mg/dL?

<100 mg/dL


20
New cards

What non-HDL goal accompanies an LDL goal <55 mg/dL?

<85 mg/dL


21
New cards

Which lipoprotein fractions make up total cholesterol?

HDL + LDL + VLDL

22
New cards

Which three values do most laboratories directly measure on a lipid panel?

Total cholesterol, triglycerides, HDL

23
New cards

Which equation does the lecture emphasize for estimating LDL-C?

Martin-Hopkins equation

24
New cards

What is the Martin-Hopkins LDL-C formula presented in lecture?

LDL-C = total cholesterol − HDL − (triglycerides/flexible factor)

25
New cards

What determines the flexible factor in the lecture’s LDL-C equation?

Triglyceride level

26
New cards

What primarily determines lipoprotein(a) levels?

Genetics

27
New cards

How do diet and activity affect lipoprotein(a), according to lecture?

They do not affect its level

28
New cards

Is lipoprotein(a) included in a standard lipid panel?

No; a specific blood test is required

29
New cards

How often should all adults have lipoprotein(a) measured according to lecture?

At least once

30
New cards

What lipoprotein(a) threshold is listed as an ASCVD risk-enhancing factor?

≥50 mg/dL

31
New cards

What structural protein is found on plaque-forming lipoprotein particles?

Apolipoprotein B

32
New cards

What apolipoprotein B level is listed as a risk-enhancing factor?

≥120 mg/dL

33
New cards

What high-sensitivity CRP level is listed as a risk-enhancing factor?

≥2 mg/L

34
New cards

What persistently elevated LDL-C range is listed as a risk-enhancing factor?

160–189 mg/dL

35
New cards

Which inflammatory diseases are listed as ASCVD risk enhancers?

Rheumatoid arthritis and SLE

36
New cards

Which ethnic groups are specifically listed as ASCVD risk enhancers?

South Asian and Filipino

37
New cards

What family history is an ASCVD risk-enhancing factor?

Premature ASCVD

38
New cards

Which prior pregnancy complications are listed as ASCVD risk enhancers?

Preeclampsia, gestational diabetes, gestational hypertension

39
New cards

At what age does routine adult fasting lipid screening begin in lecture?

19 years

40
New cards

What is the routine adult lipid screening interval in lecture?

At least every 5 years

41
New cards

Who needs more frequent lipid screening?

Patients with additional risk factors

42
New cards

At what age should children be screened for familial hypercholesterolemia?

9–11 years

43
New cards

Which adults should have 10-year and 30-year ASCVD risk calculated?

Ages 30–79 without established ASCVD

44
New cards

Which ASCVD risk equation is emphasized in lecture?

PREVENT-ASCVD

45
New cards

What additional social factor does PREVENT-ASCVD include according to lecture?

Socioeconomic status

46
New cards

Which imaging test can refine borderline or intermediate ASCVD risk?

Coronary artery calcium scoring

47
New cards

What imaging technique measures coronary artery calcium?

Noncontrast cardiac-gated CT

48
New cards

What is the lecture’s low 10-year ASCVD risk category?

<3%


49
New cards

What is the lecture’s borderline 10-year ASCVD risk category?

3% to <5%


50
New cards

What is the lecture’s intermediate 10-year ASCVD risk category?

5% to <10%

51
New cards

What is the lecture’s high 10-year ASCVD risk category?

≥10%

52
New cards

Which medication class is nearly always first-line for LDL lowering?

Statins

53
New cards

What statin therapy is recommended for clinical ASCVD?

Maximally tolerated statin therapy

54
New cards

What LDL-C level prompts treatment regardless of calculated risk in the lecture’s text?

190 mg/dL


55
New cards

What should be evaluated when LDL-C is >190 mg/dL?

Secondary causes

56
New cards

What statin therapy is recommended for LDL-C >190 mg/dL?

Maximally tolerated statin therapy

57
New cards

According to slide 48, what LDL-C threshold identifies statin benefit in adults ages 40–75 with diabetes and no ASCVD?

70 mg/dL


58
New cards

According to slide 49, what LDL-C threshold accompanies moderate-intensity statin initiation in adults ages 40–75 with diabetes and no ASCVD?

100 mg/dL


59
New cards

What 10-year ASCVD risk threshold identifies statin benefit in adults ages 40–75 without diabetes or ASCVD and LDL-C 70–189 mg/dL?

≥3%

60
New cards

What statin intensity does the primary-prevention flowchart recommend at borderline risk when treatment is chosen?

Moderate intensity

61
New cards

What statin intensity does the primary-prevention flowchart recommend at intermediate risk?

Moderate to high intensity

62
New cards

What statin intensity does the primary-prevention flowchart recommend at high risk?

High intensity

63
New cards

What LDL-C reduction is expected from high-intensity statins?

≥50%

64
New cards

What LDL-C reduction is expected from moderate-intensity statins?

30–49%

65
New cards

What LDL-C reduction is expected from low-intensity statins?

66
New cards

What atorvastatin doses are high intensity?

40–80 mg

67
New cards

What rosuvastatin doses are high intensity?

20–40 mg

68
New cards

What atorvastatin doses are moderate intensity?

10–20 mg

69
New cards

What rosuvastatin doses are moderate intensity?

5–10 mg

70
New cards

What simvastatin doses are moderate intensity?

20–40 mg

71
New cards

What pravastatin doses are moderate intensity?

40–80 mg

72
New cards

What lovastatin doses are moderate intensity?

40–80 mg

73
New cards

What pitavastatin doses are moderate intensity?

1–4 mg

74
New cards

What fluvastatin regimens are moderate intensity?

XL 80 mg or 40 mg twice daily

75
New cards

What simvastatin dose is low intensity?

10 mg

76
New cards

What pravastatin doses are low intensity?

10–20 mg

77
New cards

What lovastatin dose is low intensity?

20 mg

78
New cards

What fluvastatin doses are low intensity?

20–40 mg

79
New cards

Which enzyme do statins inhibit?

HMG-CoA reductase

80
New cards

How do statins affect hepatic uptake of circulating LDL?

Increase LDL uptake

81
New cards

How do statins affect HDL?

Modest increase

82
New cards

How do statins affect triglycerides?

Substantial decrease

83
New cards

How do statins affect CRP?

Marked decrease

84
New cards

What muscle-related statin adverse effect is explicitly listed?

Muscle aches

85
New cards

What nonmuscular statin adverse effects are listed?

GI symptoms

86
New cards

How is statin intolerance commonly defined in the lecture notes?

Inability or perceived inability to tolerate at least two different statin therapies

87
New cards

What low-dose trial is included in the lecture’s definition of statin intolerance?

At least one attempt at the lowest approved dose

88
New cards

What alternative dosing strategy is mentioned when evaluating statin intolerance?

Alternate-day dosing

89
New cards

Which three second-line LDL-lowering options are listed?

Ezetimibe, PCSK9 inhibitors, bempedoic acid

90
New cards

What documented medication problem is an indication for second-line lipid therapy?

Statin intolerance

91
New cards

In possible familial hypercholesterolemia with baseline LDL >190 mg/dL, what persistent LDL level supports second-line therapy?

100 mg/dL

92
New cards

What is ezetimibe’s mechanism?

Inhibits intestinal absorption of dietary and biliary cholesterol

93
New cards

What is the usual ezetimibe dose?

10 mg orally daily

94
New cards

What is the benefit of adding ezetimibe to a statin?

Additional LDL reduction

95
New cards

What adverse effects are listed for ezetimibe?

Diarrhea, abdominal pain, gas, fatigue

96
New cards

How do PCSK9 inhibitors increase LDL-receptor availability?

Prevent PCSK9-mediated LDL-receptor degradation

97
New cards

Which PCSK9 agents are human monoclonal antibodies?

Alirocumab and evolocumab

98
New cards

Which listed PCSK9-directed agent is a small interfering RNA?

Inclisiran

99
New cards

How are PCSK9-directed agents administered?

Subcutaneous injection

100
New cards

What local adverse effect is associated with PCSK9-directed agents?

Injection-site reactions